Savara Inc (NASDAQ:SVRA) Receives $9.86 Average PT from Brokerages

Shares of Savara Inc (NASDAQ:SVRA) have been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $9.86.

Several brokerages have weighed in on SVRA. Wells Fargo & Company started coverage on Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Savara in a report on Thursday, December 19th. HC Wainwright lowered their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Finally, Evercore ISI restated an “in-line” rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a report on Wednesday, November 13th.

Savara Price Performance

Shares of SVRA opened at $2.72 on Friday. The company has a market cap of $466.81 million, a P/E ratio of -6.33 and a beta of 0.68. Savara has a fifty-two week low of $2.60 and a fifty-two week high of $5.70. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The firm’s 50 day moving average price is $3.16 and its 200 day moving average price is $3.77.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). On average, research analysts forecast that Savara will post -0.45 earnings per share for the current fiscal year.

Insider Transactions at Savara

In other Savara news, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the transaction, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Joseph S. Mccracken acquired 20,000 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of $2.95 per share, with a total value of $59,000.00. Following the completion of the acquisition, the director now directly owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their position. The disclosure for this purchase can be found here. Insiders own 5.13% of the company’s stock.

Institutional Trading of Savara

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in Savara in the third quarter valued at $67,000. Profund Advisors LLC acquired a new position in Savara in the 2nd quarter valued at about $105,000. BNP Paribas Financial Markets raised its stake in Savara by 258.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after acquiring an additional 18,534 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after acquiring an additional 4,732 shares during the period. Finally, LMR Partners LLP grew its stake in shares of Savara by 138.3% in the 3rd quarter. LMR Partners LLP now owns 36,800 shares of the company’s stock valued at $156,000 after purchasing an additional 132,900 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.